*Corresponding author:
Katsuyuki Tanabe, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, JapanReceived: January 30, 2018; Published: February 13, 2018
DOI: 10.26717/BJSTR.2018.02.000758
To view the Full Article Peer-reviewed Article PDF
Vascular endothelial growth factor (VEGF)-A is well known to be involved in the pathogenesis of diabetic nephropathy. Although it may be a promising therapeutic target, recent evidence that anti-VEGF therapy induces renal thrombotic micro-angiopathy has tempered interest in its use. We discuss the necessary conditions for future VEGF-targeting therapy against diabetic nephropathy.
Keywords: Diabetic nephropathy; VEGF-A; Endothelial dysfunction; Podocytes